Tetra Bio-Pharma Inc TBP

TOR: TBP | ISIN: CA88166Y1007 6/03/2023

0,025 CAD (0,00%)

(0,00%) 6/03/2023

Toon enkel gratis nieuws

11 februari 2023 · Tetra Bio-Pharma Announces Listing to OTCPink Market · Persbericht

22 december 2022 · REDUVO™ Marketing Approval on the Right Path · Persbericht

6 december 2022 · Tetra Bio-Pharma Announces Results of Artificial Intelligence Study of ARDS-003 Combined with Favipiravir · Persbericht

29 november 2022 · Tetra Bio-Pharma Provides Update on Patent Applications for Novel Therapeutic ARDS-003 · Persbericht

18 november 2022 · Tetra Bio-Pharma Provides Update on Its REDUVO™ New Drug Submission · Persbericht

27 oktober 2022 · Tetra Bio-Pharma Inc. Announces Second Closing of Financing with Alpha Blue Ocean · Persbericht

11 oktober 2022 · Tetra and Prepaire Jointly Apply to BARDA for Funding · Persbericht

8 september 2022 · Tetra Bio-Pharma Inc. Announces Revised Terms and First Closing of Financing with Alpha Blue Ocean · Persbericht

6 september 2022 · Tetra Collaborates with Cellvera to Develop a Potential Oral Combination Treatment for COVID-19 Patients · Persbericht

12 augustus 2022 · Tetra Bio-Pharma Inc. Secures $6,000,000 Financing from Alpha Blue Ocean · Persbericht

10 augustus 2022 · Tetra Bio-Pharma Announces Positive Preclinical Results of ARDS-003, a Novel Therapeutic for Sepsis and Viral Infections · Persbericht

12 juli 2022 · Akanda to Supply Tetra Bio-Pharma with Pharmaceutical-Grade Cannabis for FDA Trials of QIXLEEF™, a Potential Multimillion Dollar Prescription Drug · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe